Teva Stock Price Plunges After PTAB Invalidates Two U.S. Copaxone Patents

Susan Decker; Catherine Larkin

首页> 外文期刊>World intellectual property report >Teva Stock Price Plunges After PTAB Invalidates Two U.S. Copaxone Patents

【24h】

Teva Stock Price Plunges After PTAB Invalidates Two U.S. Copaxone Patents

机译：PTAB使两项美国Copaxone专利无效后，Teva股票价格暴跌

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Teva Pharmaceutical Industries Ltd. fell 3 percent Aug. 24 after a U.S. agency invalidated two of the patents protecting Copaxone, a multiple sclerosis drug that generates 20 percent of its revenue. The patents are among three being challenged at the Patent Trial and Appeal Board. The agency is scheduled to issue a final decision on the third one by Sept. 1, according to Mylan NV, which petitioned for the patents to be reviewed.

机译：梯瓦制药工业有限公司（Teva Pharmaceutical Industries Ltd.）8月24日股价下跌了3％，此前美国一家机构使保护Copaxone的两项专利无效，Copaxone是一种多发性硬化症药物，产生了20％的收入。专利是专利审判和上诉委员会提出的三项挑战之一。据Mylan NV称，该机构计划于9月1日对第三项做出最终决定，该机构请求对专利进行审查。

著录项

来源
《World intellectual property report》 |2016年第9期|27-28|共2页
作者
Susan Decker; Catherine Larkin;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Teva Copaxone Patent Maintained in Europe; Still Under Challenge in U.S. [J] . Jenny David World intellectual property report . 2014,第1期

机译：Teva Copaxone专利在欧洲拥有；在美国仍然面临挑战
2. Teva's Copaxone UK Dosage Patent Invalid as Mylan Preps Generic [J] . Peter Leung World intellectual property report . 2017,第11期

机译：Teva的Copaxone UK剂量专利无效，因为Mylan Preps通用
3. Teva's patent plea on 'Copaxone' rejected in US: Natco [J] . Chemical Weekly Group Chemical Weekly . 2014,第36期

机译：梯瓦公司关于“可可松”的专利请求在美国被拒绝：纳特科
4. Teva's Impact on the US National Patent System ("NPS"): The Mayo/Biosig/Alice ("MBA") Framework Made It a Rough Diamond -- But Rough for Ever? Teva Cuts This Diamond and Thus May Create a Historic Mega-Trend in SPL, also Internationally [C] . Sigram Schindler International Conference on Computational Science and Computational Intelligence . 2015

机译：Teva对美国国家专利制度（“ NPS”）的影响：Mayo / Biosig / Alice（“ MBA”）框架使它成为了钻石原石-但是，有史以来就难加工吗？ Teva切割这颗钻石，因此可能在国际上也创造了SPL的历史性大趋势
5. An event study of the effect of the Drug Price Competition and Patent Term Restoration Act of 1984 on stock returns of research-based and generic pharmaceutical manufacturers. [D] . Proctor, Kurt Alan. 1989

机译：对1984年《药品价格竞争和专利期限恢复法》对研究型和非专利药制造商的股票收益产生影响的事件研究。
6. Traders guns and money: The effects of mass shootings on stock prices of firearm manufacturers in the U.S. [O] . Anandasivam Gopal, Brad N. Greenwood -1

机译：交易商枪支和金钱：大规模枪击案对美国枪支制造商股价的影响
7. U.S. Monetary Policy and Stock Prices: Should the Fed Attempt to Control Stock Prices? [O] . John Tatom 2009

机译：美国货币政策和股票价格：美联储是否应该试图控制股票价格？

Teva Stock Price Plunges After PTAB Invalidates Two U.S. Copaxone Patents

摘要

著录项

相似文献

相关主题

期刊订阅